Biotech Values

[DewDiligence]

SGTX IPOs 8.05M* shares @$18.00:

https://www.globenewswire.com/news-release/2020/12/04/2139593/0/en/Sigilon-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering.html

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal storage disorders. The engineered cells are protected by Sigilon’s Afibromer biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

An ambitious undertaking.

*Assuming exercise of underwriter’s option.